[1] [1] Xiong S, Naduvilath T, Zang J, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review［J］. ACTA Ophthalmologica,2017, 95(6): 551-566.

[2] [2] Swiatczak B, Schaeffel F. Emmetropic, But not myopic human eyes distinguish positive defocus from calculated blur［J］. Invest Ophthalmol Vis Sci, 2021,62(3): 1-9.

[3] [3] FDA approves first contact lens indicated to slow the progression of nearsightedness in children［DB/OL］. (2019-11-15). https://www.fda.gov/news-events/press-announcements/fda-approves-first-contact-lens-indicated-slow-progression-nearsightedness-children

[4] [4] Yi S, Huang Y, Yu S Z, et al. Therapeutic effect of atropine 1% in children with low myopia［J］. J AAPOS, 2015, 19(5): 426-429.

[5] [5] Yam J C, Jiang Y, Tang S M, et al. Low-concentration atropine for myopia progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control［J］. Ophthalmology, 2019, 126(1): 113-124.

[6] [6] Xiong F, Mao T, Liao H, et al. Orthokeratology and low-intensity laser therapy for slowing the progression of myopia in children［J］. Biomed Res Int, 2021, 8915867.

[7] [7] Jiang Y, Zhou Z, Tan X, et al. Effect of repeated low-lever red-light therapy in myopia control in children: A multicenter Randomized Controlled Trial［J］. Ophthalmology, 2021,S0161-6420(21)00916-7.

[9] [9] Ruiz-Pomeda A, Pérez-Sánchez B, Valls I, etal. Misight assessment study spain (MASS). A 2-year randomized clinical trial［J］. Graefes Arch Clin Exp Ophthalmol, 2018, 256(5): 1011-1021.

[10] [10] Chamberlain P, Peixoto-de-Matos S C, Logan N S, et al. A 3-year randomized clinical trial of Misight lenses for myopia control［J］. Optom Vis Sci, 2019, 96(8): 556-567.

[11] [11] Yam J C, Li F F, Zhang X, et al. Two-year clinical trial of the low-Concentration atropine for myopia progression (LAMP) study［J］. Ophthalmology, 2020, 127(7): 910-919.